Axsome Therapeutics, Inc (AXSM)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow AXSM in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on AXSM and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
AXSM at a glance
Key statistics
$8.36B
Market capitalization
- Previous close
- $159.58
- Open
- $159.70
- Day range
- $157.03 – $161.43
- Volume
- 265.0K
- Average volume (30 sessions)
- 823.6K
- Shares outstanding
- 52.38M
- Earnings per share
- $(3.66)
- Price / book
- 100.3
- Price / sales
- 10.8
- Beta (1 year, vs SPY)
- 0.60
Where the price sits in its year
52-week range
25% of the range
- Below the 52-week high
- -39.5%
- Above the 52-week low
- +27.4%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $174.60-8.6%
- 50-day average
- $195.58-18.4%
- 200-day average
- $200.35-20.3%
In the band below 30 that convention calls oversold. Weak trends can stay there for weeks.
+2.1%
1 week
-22.3%
1 month
-33.4%
3 months
-12.6%
Year to date
+24.7%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with AXSM
AXSM on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on AXSM.
See the plans →
Every planScreen names like AXSM
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on AXSM
Put AXSM on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on AXSM
See whether there is an open premium alert on AXSM, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
AXSM headlines
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
GlobeNewswire Inc. · Jul 14, 2026
- Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
GlobeNewswire Inc. · Jun 26, 2026
- Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
GlobeNewswire Inc. · Jun 4, 2026
- Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
GlobeNewswire Inc. · Jun 1, 2026
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc. · May 27, 2026
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
GlobeNewswire Inc. · Apr 8, 2026
- Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
GlobeNewswire Inc. · Dec 31, 2025
- Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
GlobeNewswire Inc. · Jun 20, 2025
SEC Form 4, most recent first
Insider filings
Jacobson Mark L.
−10.0K
Chief Operating Officer · Option exercise
· Sep 3, 2026
Jacobson Mark L.
+10.0K
Chief Operating Officer · Option exercise
$129.50K · Sep 3, 2026
Jacobson Mark L.
−10.0K
Chief Operating Officer · Open-market sale
$2.09M · Sep 3, 2026
TABUTEAU HERRIOT
−4.7K
Chief Executive Officer, Director, 10% owner · Open-market sale
$997.01K · Aug 6, 2026
TABUTEAU HERRIOT
+4.7K
Chief Executive Officer, Director, 10% owner · Option exercise
$23.07K · Aug 6, 2026
TABUTEAU HERRIOT
−45.0K
Chief Executive Officer, Director, 10% owner · Open-market sale
$9.54M · Aug 5, 2026
TABUTEAU HERRIOT
+45.0K
Chief Executive Officer, Director, 10% owner · Option exercise
$222.77K · Aug 5, 2026
TABUTEAU HERRIOT
−4.7K
Chief Executive Officer, Director, 10% owner · Option exercise
· Aug 6, 2026
About Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Employees
- 925
- Listed since
- Nov 19, 2015
- Website
- axsome.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.